

## 7 Publikationen

### 7.1 Journalartikel

Schurad, B., Tack, J., Lipp, R.; Evaluation of the transdermal permeation behavior of proterguride from drug in adhesive matrix patches through hairless mouse skin; Drug Dev. Ind. Pharm. 31 (6), (2005), 505-513

Schurad, B., Horowski, R., Jähnichen, S., Görnemann, T., Tack, J., Pertz, H. H.; Proterguride, a highly potent dopamine receptor agonist promising for transdermal administration: Interactions with  $\alpha_1$ -, 5-HT<sub>2</sub>- and H<sub>1</sub>-receptors; Life Sci., "in press"

Schurad, B., Tack, J., Lipp, R.; Transdermal delivery of the highly potent dopamine receptor agonist proterguride from acrylate-vinylacetate-matrices: Influence of N-alkylpyrrolidones; "submitted"

Schurad, B., Tack, J., Lipp, R.; Transdermal delivery of the highly potent dopamine receptor agonist proterguride from acrylate-vinylacetate-matrices: Influence of Azone<sup>®</sup> on drug release and in vitro skin permeation; in Vorbereitung

Schurad, B., Tack, J., Lipp, R.; Membrane-controlled transdermal drug delivery systems containing the highly potent dopamine receptor agonist proterguride; in Vorbereitung

Hofmann, C., Penner, U., Dorow, R., Pertz, H., Jähnichen, S., Horowski, R., Latté, K.-P., Palla, D., Schurad, B.; Lisuride, a dopamine receptor agonist with serotonin 5-HT<sub>2B</sub> receptor antagonist properties: Absence of cardiac valvulopathy ADR reports supports the concept of a crucial role for 5-HT<sub>2B</sub> receptor agonism in cardiac valvular fibrosis; Clin. Neuropharmacol., "accepted for publication"

## 7.2 Kongressbeiträge: Poster und Abstracts

Schurad, B., Tack, J., Lipp, R.; Transdermal delivery of the dopamine agonist proterguride from drug in adhesive matrix systems; Jahrestagung der DPhG 2004, 06.-09.10.2004, Regensburg, Abstract book, (2004), 162, (P T47)

Schurad, B., Tack, J., Lipp, R., Chemical enhancement of percutaneous absorption of proterguride by N-alkylpyrrolidones; EUFEPS 2004 – 8<sup>th</sup> European Congress of Pharmaceutical Sciences, 17.-20.10.2004, Brüssel, Eur. J. Pharm. Sci. 23 (Suppl. 1), (2004), 57, (PO-66)

Schurad, B., Horowski, R., Tack, J., Lipp, R.; The dopamine agonist proterguride: New pharmaceutical development; 16<sup>th</sup> International Congress on Parkinson's Disease and Related Disorders, 05.-09.06.2005, Berlin, Parkinsonism Relat. D. 11 (Suppl. 2), (2005), 240-241, (PT039-06)

Schurad, B., Tack, J., Horowski, R., Lipp, R.; Membrane-moderated transdermal drug delivery systems of the dopamine agonist proterguride; Jahrestagung der DPhG 2005, 05.-08.10.2005, Mainz, Abstract book, (2005), 142, (P T38)

Pertz, H. H., Görnemann, T., Schurad, B., Jähnichen, S.; Effects of antiparkinsonian drugs of the ergoline family at histamine H<sub>1</sub> receptors; Jahrestagung der DPhG 2005, 05.-08.10.2005, Mainz, Abstract book, (2005), 149, (P P19)